Drug Profile
Research programme: rivastigmine transdermal - Samyang
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Samyang Biopharmaceuticals Corporation; Samyang Group
- Developer Samyang Biopharmaceuticals Corporation
- Class Antidementias; Phenylcarbamates; Small molecules
- Mechanism of Action Acetylcholinesterase inhibitors; Butyrylcholinesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in South Korea (Transdermal, Patch)
- 20 Aug 2012 Research programme: rivastigmine transdermal - Samyang is available for licensing in World as of 20 Aug 2012. http://www.samyangbiopharm.com
- 31 Dec 2010 Preclinical trials in Alzheimer's disease in South Korea (Transdermal)